Mereo BioPharma Group plc (NASDAQ:MREO) Shares Purchased by Golden State Equity Partners

Golden State Equity Partners grew its holdings in shares of Mereo BioPharma Group plc (NASDAQ:MREO) by 41.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,300 shares of the company’s stock after buying an additional 5,900 shares during the period. Golden State Equity Partners’ holdings in Mereo BioPharma Group were worth $47,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in MREO. Clear Harbor Asset Management LLC grew its stake in shares of Mereo BioPharma Group by 12.3% in the third quarter. Clear Harbor Asset Management LLC now owns 63,754 shares of the company’s stock worth $82,000 after purchasing an additional 7,000 shares in the last quarter. Formidable Asset Management LLC acquired a new stake in shares of Mereo BioPharma Group in the 3rd quarter worth approximately $428,000. Tejara Capital Ltd boosted its holdings in shares of Mereo BioPharma Group by 5.8% in the third quarter. Tejara Capital Ltd now owns 3,215,001 shares of the company’s stock valued at $4,147,000 after acquiring an additional 177,030 shares in the last quarter. 683 Capital Management LLC increased its stake in shares of Mereo BioPharma Group by 11.1% during the third quarter. 683 Capital Management LLC now owns 6,000,000 shares of the company’s stock valued at $7,740,000 after acquiring an additional 600,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Mereo BioPharma Group during the third quarter worth approximately $1,032,000. 62.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Mereo BioPharma Group in a research note on Wednesday, April 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Mereo BioPharma Group in a research note on Thursday, March 28th.

Mereo BioPharma Group Stock Down 2.5 %

MREO stock opened at $2.74 on Monday. The firm has a 50-day moving average of $3.23 and a two-hundred day moving average of $2.76. Mereo BioPharma Group plc has a one year low of $0.92 and a one year high of $4.36. The company has a quick ratio of 6.72, a current ratio of 6.72 and a debt-to-equity ratio of 0.09.

Mereo BioPharma Group Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.